A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome

Cancer Genetics

Volumn 208, Issue 1-2, 2015, Pages 47-51

  Id Said, Badr ^a,b   Malkin, David ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Li Fraumeni syndrome; MicroRNA; P53; Single nucleotide polymorphism

Indexed keywords

ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; FAMILIAL CANCER; GENE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MICRORNA 605 GENE; ONSET AGE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; CELL MOTION; CLASSIFICATION; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MALE; MOLECULAR GENETICS; MUTATION; NEOPLASMS; NUCLEOTIDE SEQUENCE; PATHOLOGY; RHABDOMYOSARCOMA; TUMOR CELL LINE;

MICRORNA; MIRN605 MICRORNA, HUMAN; PROTEIN MDM2; PROTEIN P53;

AGE OF ONSET; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LI-FRAUMENI SYNDROME; MALE; MICRORNAS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RHABDOMYOSARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84924540717     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.12.003     Document Type: Article

References (19)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Friedman R.C., Farh K.K., Burge C.B., et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
3. Deng S., Calin G.A., Croce C.M., et al. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008, 7:2643-2646.
4. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010, 10:389-402.
5. Olivier M., Goldgar D.E., Sodha N., et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003, 63:6643-6650.
6. Bougeard G., Sesboüé R., Baert-Desurmont S., et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. JMed Genet 2008, 45:535-538.
7. Tabori U., Nanda S., Druker H., et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007, 67:1415-1418.
8. Marcel V., Palmero E.I., Falagan-Lotsch P., et al. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. JMed Genet 2009, 46:766-772.
9. Ruijs M.W., Schmidt M.K., Nevanlinna H., et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007, 15:110-114.
10. Bougeard G., Baert-Desurmont S., Tournier I., et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. JMed Genet 2006, 43:531-533.
11. Shlien A., Tabori U., Marshall C.R., et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A 2008, 105:11264-11269.
12. Aury-Landas J., Bougeard G., Castel H., et al. Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li-Fraumeni syndrome with brain tumours. Eur J Hum Genet 2013, 21:1369-1376.
13. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012, 12:613-626.
14. Xiao J., Lin H., Luo X., et al. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 2011, 30:524-532.
15. Zhang M.W., Jin M.J., Yu Y.X., et al. Associations of lifestyle-related factors, hsa-miR-149 and hsa-miR-605 gene polymorphisms with gastrointestinal cancer risk. Mol Carcinog 2012, 51(Suppl 1):E21-E31.
16. Hu Y., Yu C.Y., Wang J.L., et al. MicroRNA sequence polymorphisms and the risk of different types of cancer. Sci Rep 2014, 4:3648.
17. Dahiya N., Sherman-Baust C.A., Wang T.L., et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008, 3:e2436.
18. Hofacker I.L. Vienna RNA secondary structure server. Nucleic Acids Res 2003, 31:3429-3431.
19. Bond G.L., Hu W., Bond E.E., et al. Asingle nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.